Pfizer to reveal Aromasin, neratinib and Sutent clinical trial results

Pfizer has announced that it will soon unveil the results of clinical studies into its breast cancer therapies Aromasin (exemestane tablets), neratinib and Sutent (sunitinib malate) in metastatic breast cancer.

Among the evidence to be presented is the efficacy and safety of neratinib in combination with paclitaxel in the HER2 positive version of the disease.

As well as this, the final results of the firm’s phase III trial evaluating single-agent sunitinib versus single-agent capecitabine will also be presented as a treatment for patients with HER2 negative advanced breast cancer after failure of standard treatment.

“We are pleased to share research from our expanded pipeline, including neratinib and sunitinib, which builds upon our strong heritage in breast cancer research with Aromasin,” commented Maria Koehler, vice-president of women’s cancers strategy for Pfizer Oncology.

In other Pfizer news, the firm revealed earlier this month that it will collaborate with Protalix for the development and commercialisation of the Gaucher’s disease treatment taliglucerase alfa – a plant-cell expressed form of glucocerebrosidase.